

HKVCA Healthcare and Biotech Seminar

30 November, 2018

Sponsored by: **Deloitte.**



Vanessa Huang, General Partner, BVCF Management

Vanessa Huang is a General Partner at BVCF Management, one of China's first U.S. dollar healthcare VC funds. Vanessa has over 20 years of experience in healthcare and investment banking in the U.S. and Hong Kong. Prior to joining BVCF, Vanessa was Head of Emerging Asia Healthcare Investment Banking at J.P. Morgan. Vanessa has biotech industry experience at Amgen, Inc, and holds an MBA from The Wharton School, University of Pennsylvania.



Edward Au, Partner, Audit & Assurance, Deloitte

Edward Au has been Audit Partner of Deloitte China since 2003 and has extensive experience in auditing companies in Hong Kong, Singapore, the U.S., and the Chinese Mainland.

He is also Co-Leader of National Public Offering Group of the China Firm and has been actively involved in various debt and equity offering projects in Hong Kong, the U.S., and Singapore. He is also Vice Chairman of the Corporate Finance Advisory Panel of Hong Kong Institute of Certified Public Accountants.

He focuses on International Finance Reporting Standards/ U.S. Generally Accepted Accounting Principles and reporting matters related to Hong Kong Stock Exchange/ U.S. Securities & Exchange Commission. In addition, he has sound experience in leading our teams in the region to serve local and multinational clients from a variety of industries.



Will Liu, Partner, Eight Roads Capital

Dr. Will Liu is a Partner of Eight Roads Ventures China, specializing in healthcare investment with twenty years of experience in the pharmaceutical and biotech industries.

Prior to joining Eight Roads, Will held several positions of business development in multinational pharmaceutical companies, including Head of Worldwide Business Development for Neurosciences at GSK and Head of External Innovation China at Merck KGaA. Will was trained as a scientist and worked in drug discovery for over ten years.

Will graduated from Nankai University in China and received his Ph.D. degree from the University of Michigan.



Judith Li, Partner, Lilly Asia Ventures

Judith J. Li, is a Partner at Lilly Asia Ventures (LAV), based in Hong Kong / Shanghai and focused on early and growth stage investments across biopharmaceuticals, medical devices, and diagnostics both domestically and cross-border. Judith holds board appointments at a variety of LAV's portfolio companies, including Nextcure, Just Biotherapeutics, Gritstone Oncology, and Tmunity. Her prior experience includes McKinsey's New York office, hospital administration at

Partners Healthcare, and co-founding an interventional nephrology medical device venture. Judith holds a B.A. in Neurobiology from Harvard and M.B.A. from Harvard Business School, and currently resides in Hong Kong, splitting her time between Hong Kong, Shanghai, and the Bay Area.



Bosun Hau, Managing Director & Partner, Sailing Capital

Bosun is a Managing Director and Partner for Sailing Capital. Bosun leads global healthcare but also covers TMT and food/agriculture technology investments for Sailing. He also is a member of Sailing's Investment and Risk Committees.

Based in Hong Kong and Shanghai, he has 15 years of healthcare and investment experience, primarily as a healthcare and TMT investor in both private and publicly-listed companies in the US, EU and China. Prior to joining Sailing, Bosun was a Partner at MVM Life Science Partners in Boston and London. He also has experience at JP Morgan in New York, McKinsey & Company in Singapore, Eli Lilly & Company and S.R. One, GlaxoSmithKline's Corporate Venture Group. Bosun is or has been a Board Director or Observer for several leading public and private biotechnology, medical technology, specialty pharmaceutical and food technology companies.